RECCE PHARMACEUTICALS LTD - Announcements

Market Cap $135.6M Add to my watchlist

Healthcare

An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce... An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of synthetic anti-infectives.More

Corporate Spotlight

An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of synthetic anti-infectives.
View the full Corporate Spotlight

RCE UPDATE HIGHLIGHTS KEY DEVELOPMENTS FOR UPSIDE

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

RCE	China Patent Granted for RECCE Anti-Infectives	PRICE SENSITIVE	07/05/24	241.55KB	Share
RCE	Safety Committee Approves High Dose of 4,000mg	PRICE SENSITIVE	26/04/24	263.52KB	Share
RCE	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	22/04/24	575.83KB	Share
RCE	Recce Completes 5,000 R327 Doses Per Week under GMP	PRICE SENSITIVE	16/04/24	217.27KB	Share
RCE	Recce Pharmaceuticals - Business Update	PRICE SENSITIVE	08/04/24	582.67KB	Share
RCE	Patent Granted in Israel for RECCE Anti-Infectives	PRICE SENSITIVE	03/04/24	324.65KB	Share
RCE	Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial	PRICE SENSITIVE	15/03/24	278.98KB	Share
RCE	Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial	PRICE SENSITIVE	12/03/24	262.97KB	Share
RCE	Recce Receives AUD $11.17m R&D Advance	PRICE SENSITIVE	08/03/24	238.07KB	Share
RCE	Appendix 4D and Interim Financial Report	PRICE SENSITIVE	27/02/24	464.55KB	Share
RCE	Safety Committee Approves Expansion of Ph I/II DFI Trial	PRICE SENSITIVE	26/02/24	246.18KB	Share
RCE	RCE Establishes Strategic Partnership in South-East Asia	PRICE SENSITIVE	06/02/24	451.89KB	Share
RCE	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/01/24	746.24KB	Share
RCE	Positive Ph I/II DFI Efficacy Data to Support Site Expansion	PRICE SENSITIVE	18/01/24	266.33KB	Share
RCE	Murdoch Children's R327 Efficacy UTI in-vivo	PRICE SENSITIVE	28/12/23	384.21KB	Share
RCE	RCE Awarded Further $11.17m Advanced Overseas Finding	PRICE SENSITIVE	15/12/23	382.33KB	Share
RCE	RCE Awarded $43.7m AusIndustry Advanced Overseas Finding	PRICE SENSITIVE	14/12/23	376.84KB	Share
RCE	Murdoch Children's R327 Efficacy N.gonorrhoeae in-vivo	PRICE SENSITIVE	14/12/23	375.27KB	Share
RCE	Canadian Patent Granted for RECCE Anti-Infectives	PRICE SENSITIVE	23/11/23	320.09KB	Share
RCE	Subjects Dosed Over 15 mins in UTI/Urosepsis Clinical Trial	PRICE SENSITIVE	07/11/23	230.98KB	Share
RCE	Committee Approves Fast 15-Min Infusion in Ph I/II Urosepsis	PRICE SENSITIVE	24/10/23	305.03KB	Share
RCE	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	20/10/23	1.02MB	Share
RCE	Completes Cohort Dosing UTI/Urosepsis Rapid Infusion Trial	PRICE SENSITIVE	22/09/23	268.92KB	Share
RCE	Placement and Entitlement Offer	PRICE SENSITIVE	11/09/23	276.98KB	Share
RCE	Trading Halt	PRICE SENSITIVE	08/09/23	317.42KB	Share
RCE	Opening R&D Address at World AMR Congress	PRICE SENSITIVE	08/09/23	3.23MB	Share
RCE	RECCE Trademark Registered - Vietnam	PRICE SENSITIVE	06/09/23	289.61KB	Share
RCE	Additional Positive Patient Cases - Special Access Scheme	PRICE SENSITIVE	31/08/23	497.11KB	Share
RCE	Appendix 4E and Unaudited Preliminary Report	PRICE SENSITIVE	31/08/23	503.53KB	Share
RCE	Next Dose Cleared in Rapid Infusion Phase I/II UTI Trial	PRICE SENSITIVE	28/08/23	256.66KB	Share
RCE	Patients Dosed in R327 Diabetic Foot Infection Trial	PRICE SENSITIVE	22/08/23	281.98KB	Share
RCE	Phase I/II Burn Wound Infection Trial Stage 1 Complete	PRICE SENSITIVE	21/08/23	349.53KB	Share
RCE	Positive Patients Update - Special Access Scheme	PRICE SENSITIVE	08/08/23	537.59KB	Share
RCE	Australian Patent Granted for RECCE Anti-Infectives	PRICE SENSITIVE	03/08/23	318.83KB	Share
RCE	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/23	480.05KB	Share
RCE	Bonus Canadian R&D Rebate Received	PRICE SENSITIVE	28/07/23	265.44KB	Share
RCE	Scientia Completes Cohort Dosing in Phase I/II UTI Trial	PRICE SENSITIVE	28/07/23	273.47KB	Share
RCE	Scientia Doses Ahead of Schedule in Phase I/II UTI Trial	PRICE SENSITIVE	24/07/23	273.72KB	Share
RCE	Clarification - 5x Higher Concentration in Urine & Plasma	PRICE SENSITIVE	20/07/23	168.73KB	Share
RCE	Phase I Clinical Trial Data Review Complete	PRICE SENSITIVE	19/07/23	631.65KB	Share
RCE	A$801,604 R&D Rebate Advance Received	PRICE SENSITIVE	12/07/23	223.17KB	Share
RCE	First Cohort Dosed in Rapid Infusion Phase I/II UTI study	PRICE SENSITIVE	10/07/23	266.1KB	Share
RCE	Ethics Approval for Phase I/II UTI Trial Expansion	PRICE SENSITIVE	29/06/23	280.54KB	Share
RCE	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/23	710.13KB	Share
RCE	Ethics Approval to Start Phase I/II (I.V.) Clinical Trial	PRICE SENSITIVE	17/04/23	258.68KB	Share
RCE	New Family 4 Patent to be Granted for RECCE Anti-Infectives	PRICE SENSITIVE	11/04/23	272.7KB	Share
RCE	Recce Receives Further A$973,144 R&D Advance	PRICE SENSITIVE	04/04/23	220.97KB	Share
RCE	Corporate Presentation - WI Emergence 2023	PRICE SENSITIVE	23/03/23	2.82MB	Share
RCE	Appendix 4D and Interim Financial Report	PRICE SENSITIVE	27/02/23	312KB	Share
RCE	Recce Selects CMAX for Phase I/II UTI Clinical Trial	PRICE SENSITIVE	20/02/23	393.65KB	Share
RCE	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/01/23	613.04KB	Share
RCE	A$6.21m Received from R&D Rebate Payments	PRICE SENSITIVE	25/01/23	317.75KB	Share
RCE	JP Morgan Healthcare Conference	PRICE SENSITIVE	10/01/23	3.42MB	Share
RCE	Australian Patent to be Granted for RECCE Anti-Infectives	PRICE SENSITIVE	10/01/23	250.74KB	Share
RCE	Anti-Infective Research Unit est. at Murdoch Children's	PRICE SENSITIVE	15/12/22	319.96KB	Share
RCE	Approval to Start Phase I/II Diabetic Foot Ulcer Study	PRICE SENSITIVE	09/12/22	329.13KB	Share
RCE	Trading Halt	PRICE SENSITIVE	07/12/22	643.19KB	Share
RCE	Pause in Trading	PRICE SENSITIVE	07/12/22	113.49KB	Share
RCE	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/10/22	581.3KB	Share
RCE	Anti-Infective Portfolio Update and Webinar details	PRICE SENSITIVE	19/10/22	3.36MB	Share
RCE	Pause in Trading	PRICE SENSITIVE	19/10/22	115.99KB	Share
RCE	R327 COVID Study Update	PRICE SENSITIVE	18/10/22	398.4KB	Share
RCE	Pause in trading	PRICE SENSITIVE	18/10/22	115.68KB	Share
RCE	Expansion and Acceleration of Clinical Programs	PRICE SENSITIVE	27/09/22	308.99KB	Share
RCE	Appendix 4E	PRICE SENSITIVE	31/08/22	244.24KB	Share
RCE	Phase I Clinical Trial of R327 I.V. - 6000mg Complete	PRICE SENSITIVE	22/08/22	313.84KB	Share
RCE	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	01/08/22	944.67KB	Share
RCE	Corporate Presentation - Aussie Equities Day 2022	PRICE SENSITIVE	28/07/22	2.22MB	Share
RCE	Phase I Positive Safety Data - 4000mg Complete	PRICE SENSITIVE	21/06/22	241.36KB	Share
RCE	Phase I Clinical Trial R327 Advances to 4000mg	PRICE SENSITIVE	20/05/22	241.06KB	Share
RCE	Corporate Presentation - Biotech Investor Lunch	PRICE SENSITIVE	16/05/22	2.48MB	Share
RCE	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	02/05/22	436.79KB	Share
RCE	Phase I Clinical Trial R327 Advances to High Dose Cohort	PRICE SENSITIVE	12/04/22	408.22KB	Share
RCE	Anti-Viral Patent Granted in Hong Kong	PRICE SENSITIVE	11/04/22	225.31KB	Share
RCE	Positive safety data from 4th Cohort -Phase I Clinical Trial	PRICE SENSITIVE	30/03/22	247.62KB	Share
RCE	$3.08m R&D Rebate Received	PRICE SENSITIVE	28/03/22	238.52KB	Share
RCE	Safety Committee Clears PhI R327 Dose Increase	PRICE SENSITIVE	07/03/22	265.52KB	Share
RCE	S&P DJI Announces March 2022 Quarterly Rebalance	PRICE SENSITIVE	04/03/22	175.5KB	Share
RCE	Appendix 4D and Interim Financial Report	PRICE SENSITIVE	28/02/22	265.76KB	Share
RCE	Positive Safety Continues in 3rd Cohort PhI Clinical Trial	PRICE SENSITIVE	21/02/22	266.79KB	Share
RCE	Positive Safety Data from Third Cohort of PI Clinical Trial	PRICE SENSITIVE	08/02/22	247.91KB	Share
RCE	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/22	441.2KB	Share
RCE	Positive Safety Data from Second Cohort of PI Clinical Trial	PRICE SENSITIVE	18/01/22	267.69KB	Share
RCE	Positive Safety Data from Phase 1 Clinical Trial	PRICE SENSITIVE	07/01/22	316.58KB	Share
RCE	Patients to be Dosed in Ph 1 IV Clinical Trial of R327	PRICE SENSITIVE	15/12/21	246.15KB	Share
RCE	Update on Phase I/II Clinical Trial for Burn Wound Infection	PRICE SENSITIVE	07/12/21	273.37KB	Share
RCE	Opening R&D Address at World AMR Congress	PRICE SENSITIVE	08/11/21	6.74MB	Share
RCE	Appendix 4C and Activity Report	PRICE SENSITIVE	29/10/21	413.29KB	Share
RCE	Ethics Approval to Start Phase 1 Intravenous Clinical Trial	PRICE SENSITIVE	25/10/21	247.07KB	Share
RCE	Reinstatement to Official Quotation	PRICE SENSITIVE	12/10/21	85.72KB	Share
RCE	Court Orders Granted	PRICE SENSITIVE	12/10/21	404.72KB	Share
RCE	Suspension from Official Quotation	PRICE SENSITIVE	12/10/21	240.35KB	Share
RCE	Trading halt	PRICE SENSITIVE	08/10/21	696.71KB	Share
RCE	Pause in Trading	PRICE SENSITIVE	08/10/21	116.55KB	Share
RCE	R327 Phase I Clinical Trial Registered on ANZCTR	PRICE SENSITIVE	30/09/21	288.3KB	Share
RCE	Appendix 4E	PRICE SENSITIVE	31/08/21	261.73KB	Share
RCE	Recce Receives Further Innovation Connections Grant	PRICE SENSITIVE	11/08/21	225.61KB	Share
RCE	Appendix 4C and Activity Report	PRICE SENSITIVE	30/07/21	433.45KB	Share
RCE	Anti-Viral Patent Granted in USA for RECCE Anti-Infectives	PRICE SENSITIVE	22/07/21	270.51KB	Share
RCE	Anti-Viral Patent Granted in China	PRICE SENSITIVE	20/07/21	270.49KB	Share

RCE China Patent Granted for RECCE Anti-Infectives
07/05/24	PRICE SENSITIVE	241.55KB	Share
RCE Safety Committee Approves High Dose of 4,000mg
26/04/24	PRICE SENSITIVE	263.52KB	Share
RCE Quarterly Activities/Appendix 4C Cash Flow Report
22/04/24	PRICE SENSITIVE	575.83KB	Share
RCE Recce Completes 5,000 R327 Doses Per Week under GMP
16/04/24	PRICE SENSITIVE	217.27KB	Share
RCE Recce Pharmaceuticals - Business Update
08/04/24	PRICE SENSITIVE	582.67KB	Share
RCE Patent Granted in Israel for RECCE Anti-Infectives
03/04/24	PRICE SENSITIVE	324.65KB	Share
RCE Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
15/03/24	PRICE SENSITIVE	278.98KB	Share
RCE Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
12/03/24	PRICE SENSITIVE	262.97KB	Share
RCE Recce Receives AUD $11.17m R&D Advance
08/03/24	PRICE SENSITIVE	238.07KB	Share
RCE Appendix 4D and Interim Financial Report
27/02/24	PRICE SENSITIVE	464.55KB	Share
RCE Safety Committee Approves Expansion of Ph I/II DFI Trial
26/02/24	PRICE SENSITIVE	246.18KB	Share
RCE RCE Establishes Strategic Partnership in South-East Asia
06/02/24	PRICE SENSITIVE	451.89KB	Share
RCE Quarterly Activities/Appendix 4C Cash Flow Report
30/01/24	PRICE SENSITIVE	746.24KB	Share
RCE Positive Ph I/II DFI Efficacy Data to Support Site Expansion
18/01/24	PRICE SENSITIVE	266.33KB	Share
RCE Murdoch Children's R327 Efficacy UTI in-vivo
28/12/23	PRICE SENSITIVE	384.21KB	Share
RCE RCE Awarded Further $11.17m Advanced Overseas Finding
15/12/23	PRICE SENSITIVE	382.33KB	Share
RCE RCE Awarded $43.7m AusIndustry Advanced Overseas Finding
14/12/23	PRICE SENSITIVE	376.84KB	Share
RCE Murdoch Children's R327 Efficacy N.gonorrhoeae in-vivo
14/12/23	PRICE SENSITIVE	375.27KB	Share
RCE Canadian Patent Granted for RECCE Anti-Infectives
23/11/23	PRICE SENSITIVE	320.09KB	Share
RCE Subjects Dosed Over 15 mins in UTI/Urosepsis Clinical Trial
07/11/23	PRICE SENSITIVE	230.98KB	Share
RCE Committee Approves Fast 15-Min Infusion in Ph I/II Urosepsis
24/10/23	PRICE SENSITIVE	305.03KB	Share
RCE Quarterly Activities/Appendix 4C Cash Flow Report
20/10/23	PRICE SENSITIVE	1.02MB	Share
RCE Completes Cohort Dosing UTI/Urosepsis Rapid Infusion Trial
22/09/23	PRICE SENSITIVE	268.92KB	Share
RCE Placement and Entitlement Offer
11/09/23	PRICE SENSITIVE	276.98KB	Share
RCE Trading Halt
08/09/23	PRICE SENSITIVE	317.42KB	Share
RCE Opening R&D Address at World AMR Congress
08/09/23	PRICE SENSITIVE	3.23MB	Share
RCE RECCE Trademark Registered - Vietnam
06/09/23	PRICE SENSITIVE	289.61KB	Share
RCE Additional Positive Patient Cases - Special Access Scheme
31/08/23	PRICE SENSITIVE	497.11KB	Share
RCE Appendix 4E and Unaudited Preliminary Report
31/08/23	PRICE SENSITIVE	503.53KB	Share
RCE Next Dose Cleared in Rapid Infusion Phase I/II UTI Trial
28/08/23	PRICE SENSITIVE	256.66KB	Share
RCE Patients Dosed in R327 Diabetic Foot Infection Trial
22/08/23	PRICE SENSITIVE	281.98KB	Share
RCE Phase I/II Burn Wound Infection Trial Stage 1 Complete
21/08/23	PRICE SENSITIVE	349.53KB	Share
RCE Positive Patients Update - Special Access Scheme
08/08/23	PRICE SENSITIVE	537.59KB	Share
RCE Australian Patent Granted for RECCE Anti-Infectives
03/08/23	PRICE SENSITIVE	318.83KB	Share
RCE Quarterly Activities/Appendix 4C Cash Flow Report
31/07/23	PRICE SENSITIVE	480.05KB	Share
RCE Bonus Canadian R&D Rebate Received
28/07/23	PRICE SENSITIVE	265.44KB	Share
RCE Scientia Completes Cohort Dosing in Phase I/II UTI Trial
28/07/23	PRICE SENSITIVE	273.47KB	Share
RCE Scientia Doses Ahead of Schedule in Phase I/II UTI Trial
24/07/23	PRICE SENSITIVE	273.72KB	Share
RCE Clarification - 5x Higher Concentration in Urine & Plasma
20/07/23	PRICE SENSITIVE	168.73KB	Share
RCE Phase I Clinical Trial Data Review Complete
19/07/23	PRICE SENSITIVE	631.65KB	Share
RCE A$801,604 R&D Rebate Advance Received
12/07/23	PRICE SENSITIVE	223.17KB	Share
RCE First Cohort Dosed in Rapid Infusion Phase I/II UTI study
10/07/23	PRICE SENSITIVE	266.1KB	Share
RCE Ethics Approval for Phase I/II UTI Trial Expansion
29/06/23	PRICE SENSITIVE	280.54KB	Share
RCE Quarterly Activities/Appendix 4C Cash Flow Report
28/04/23	PRICE SENSITIVE	710.13KB	Share
RCE Ethics Approval to Start Phase I/II (I.V.) Clinical Trial
17/04/23	PRICE SENSITIVE	258.68KB	Share
RCE New Family 4 Patent to be Granted for RECCE Anti-Infectives
11/04/23	PRICE SENSITIVE	272.7KB	Share
RCE Recce Receives Further A$973,144 R&D Advance
04/04/23	PRICE SENSITIVE	220.97KB	Share
RCE Corporate Presentation - WI Emergence 2023
23/03/23	PRICE SENSITIVE	2.82MB	Share
RCE Appendix 4D and Interim Financial Report
27/02/23	PRICE SENSITIVE	312KB	Share
RCE Recce Selects CMAX for Phase I/II UTI Clinical Trial
20/02/23	PRICE SENSITIVE	393.65KB	Share
RCE Quarterly Activities/Appendix 4C Cash Flow Report
30/01/23	PRICE SENSITIVE	613.04KB	Share
RCE A$6.21m Received from R&D Rebate Payments
25/01/23	PRICE SENSITIVE	317.75KB	Share
RCE JP Morgan Healthcare Conference
10/01/23	PRICE SENSITIVE	3.42MB	Share
RCE Australian Patent to be Granted for RECCE Anti-Infectives
10/01/23	PRICE SENSITIVE	250.74KB	Share
RCE Anti-Infective Research Unit est. at Murdoch Children's
15/12/22	PRICE SENSITIVE	319.96KB	Share
RCE Approval to Start Phase I/II Diabetic Foot Ulcer Study
09/12/22	PRICE SENSITIVE	329.13KB	Share
RCE Trading Halt
07/12/22	PRICE SENSITIVE	643.19KB	Share
RCE Pause in Trading
07/12/22	PRICE SENSITIVE	113.49KB	Share
RCE Quarterly Activities/Appendix 4C Cash Flow Report
28/10/22	PRICE SENSITIVE	581.3KB	Share
RCE Anti-Infective Portfolio Update and Webinar details
19/10/22	PRICE SENSITIVE	3.36MB	Share
RCE Pause in Trading
19/10/22	PRICE SENSITIVE	115.99KB	Share
RCE R327 COVID Study Update
18/10/22	PRICE SENSITIVE	398.4KB	Share
RCE Pause in trading
18/10/22	PRICE SENSITIVE	115.68KB	Share
RCE Expansion and Acceleration of Clinical Programs
27/09/22	PRICE SENSITIVE	308.99KB	Share
RCE Appendix 4E
31/08/22	PRICE SENSITIVE	244.24KB	Share
RCE Phase I Clinical Trial of R327 I.V. - 6000mg Complete
22/08/22	PRICE SENSITIVE	313.84KB	Share
RCE Quarterly Activities/Appendix 4C Cash Flow Report
01/08/22	PRICE SENSITIVE	944.67KB	Share
RCE Corporate Presentation - Aussie Equities Day 2022
28/07/22	PRICE SENSITIVE	2.22MB	Share
RCE Phase I Positive Safety Data - 4000mg Complete
21/06/22	PRICE SENSITIVE	241.36KB	Share
RCE Phase I Clinical Trial R327 Advances to 4000mg
20/05/22	PRICE SENSITIVE	241.06KB	Share
RCE Corporate Presentation - Biotech Investor Lunch
16/05/22	PRICE SENSITIVE	2.48MB	Share
RCE Quarterly Activities/Appendix 4C Cash Flow Report
02/05/22	PRICE SENSITIVE	436.79KB	Share
RCE Phase I Clinical Trial R327 Advances to High Dose Cohort
12/04/22	PRICE SENSITIVE	408.22KB	Share
RCE Anti-Viral Patent Granted in Hong Kong
11/04/22	PRICE SENSITIVE	225.31KB	Share
RCE Positive safety data from 4th Cohort -Phase I Clinical Trial
30/03/22	PRICE SENSITIVE	247.62KB	Share
RCE $3.08m R&D Rebate Received
28/03/22	PRICE SENSITIVE	238.52KB	Share
RCE Safety Committee Clears PhI R327 Dose Increase
07/03/22	PRICE SENSITIVE	265.52KB	Share
RCE S&P DJI Announces March 2022 Quarterly Rebalance
04/03/22	PRICE SENSITIVE	175.5KB	Share
RCE Appendix 4D and Interim Financial Report
28/02/22	PRICE SENSITIVE	265.76KB	Share
RCE Positive Safety Continues in 3rd Cohort PhI Clinical Trial
21/02/22	PRICE SENSITIVE	266.79KB	Share
RCE Positive Safety Data from Third Cohort of PI Clinical Trial
08/02/22	PRICE SENSITIVE	247.91KB	Share
RCE Quarterly Activities/Appendix 4C Cash Flow Report
31/01/22	PRICE SENSITIVE	441.2KB	Share
RCE Positive Safety Data from Second Cohort of PI Clinical Trial
18/01/22	PRICE SENSITIVE	267.69KB	Share
RCE Positive Safety Data from Phase 1 Clinical Trial
07/01/22	PRICE SENSITIVE	316.58KB	Share
RCE Patients to be Dosed in Ph 1 IV Clinical Trial of R327
15/12/21	PRICE SENSITIVE	246.15KB	Share
RCE Update on Phase I/II Clinical Trial for Burn Wound Infection
07/12/21	PRICE SENSITIVE	273.37KB	Share
RCE Opening R&D Address at World AMR Congress
08/11/21	PRICE SENSITIVE	6.74MB	Share
RCE Appendix 4C and Activity Report
29/10/21	PRICE SENSITIVE	413.29KB	Share
RCE Ethics Approval to Start Phase 1 Intravenous Clinical Trial
25/10/21	PRICE SENSITIVE	247.07KB	Share
RCE Reinstatement to Official Quotation
12/10/21	PRICE SENSITIVE	85.72KB	Share
RCE Court Orders Granted
12/10/21	PRICE SENSITIVE	404.72KB	Share
RCE Suspension from Official Quotation
12/10/21	PRICE SENSITIVE	240.35KB	Share
RCE Trading halt
08/10/21	PRICE SENSITIVE	696.71KB	Share
RCE Pause in Trading
08/10/21	PRICE SENSITIVE	116.55KB	Share
RCE R327 Phase I Clinical Trial Registered on ANZCTR
30/09/21	PRICE SENSITIVE	288.3KB	Share
RCE Appendix 4E
31/08/21	PRICE SENSITIVE	261.73KB	Share
RCE Recce Receives Further Innovation Connections Grant
11/08/21	PRICE SENSITIVE	225.61KB	Share
RCE Appendix 4C and Activity Report
30/07/21	PRICE SENSITIVE	433.45KB	Share
RCE Anti-Viral Patent Granted in USA for RECCE Anti-Infectives
22/07/21	PRICE SENSITIVE	270.51KB	Share
RCE Anti-Viral Patent Granted in China
20/07/21	PRICE SENSITIVE	270.49KB	Share

REFRESH

1 2

(20min delay)
Last 66.5¢		Change 0.000(0.00%)		Mkt cap ! $135.6M

Open	High	Low	Value	Volume
66.5¢	66.5¢	65.0¢	$23.95K	36.19K

Buyers (Bids)

No.	Vol.	Price($)
1	16765	66.5¢

Sellers (Offers)

Price($)	Vol.	No.
67.0¢	74000	4

View Market Depth

No.	Vol.	Price($)
1	16765	0.665
1	25000	0.640
1	24674	0.635
1	12099	0.610
6	14402	0.600

Price($)	Vol.	No.
0.670	74000	4
0.675	50000	1
0.680	28537	3
0.690	61200	2
0.695	52037	2

Last trade - 16.10pm 08/05/2024 (20 minute delay)


Last 66.5¢		Change 0.000 ( 0.00 %)
Open	High	Low	Volume
66.5¢	66.5¢	66.5¢	411
Last updated 15.06pm 08/05/2024 ?

RCE (ASX) Chart

RECCE PHARMACEUTICALS LTD - Announcements

Corporate Spotlight

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories